Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial

Clinical Trial ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Omega-3 in SLE: a double-blind, placebo-controlled randomized clinical trial of endothelial dysfunction and disease activity in systemic lupus erythematosus

Rheumatology International ◽

10.1007/s00296-013-2811-3 ◽

2013 ◽

Vol 33 (11) ◽

pp. 2789-2796 ◽

Cited By ~ 28

Author(s):

Kayode J. Bello ◽

Hong Fang ◽

Parastoo Fazeli ◽

Waleed Bolad ◽

Mary Corretti ◽

...

Keyword(s):

Clinical Trial ◽

Endothelial Dysfunction ◽

Disease Activity ◽

Randomized Clinical Trial ◽

Lupus Erythematosus ◽

Omega 3 ◽

Systemic Lupus ◽

Double Blind ◽

A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus

Lupus ◽

10.1191/096120399678847588 ◽

1999 ◽

Vol 8 (3) ◽

pp. 181-187 ◽

Cited By ~ 91

Author(s):

R F van Vollenhoven ◽

J L Park ◽

M C Genovese ◽

J P West ◽

J L McGuire

Keyword(s):

Severe Systemic Lupus Erythematosus

Clinical Trial ◽

Lupus Erythematosus ◽

Controlled Clinical Trial ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

Arthritis & Rheumatology ◽

10.1002/art.39856 ◽

2017 ◽

Vol 69 (2) ◽

pp. 362-375 ◽

Cited By ~ 78

Author(s):

Megan E. B. Clowse ◽

Daniel J. Wallace ◽

Richard A. Furie ◽

Michelle A. Petri ◽

Marilyn C. Pike ◽

...

Keyword(s):

Lupus Erythematosus ◽

Active Systemic Lupus Erythematosus ◽

Phase Iii ◽

Controlled Trials ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Two Phase ◽

Double Blind ◽

OP0019 Baricitinib in systemic lupus erythematosus (SLE): results from a phase 2, randomised, double-blind, placebo-controlled study

10.1136/annrheumdis-2018-eular.1918 ◽

2018 ◽

Cited By ~ 1

Author(s):

D.J. Wallace ◽

R.A. Furie ◽

Y. Tanaka ◽

K.C. Kalunian ◽

M. Mosca ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Study ◽

Phase 2 ◽

Systemic Lupus ◽

Double Blind ◽

A double blind, placebo controlled trial of intravenous methylprednisolone in systemic lupus erythematosus.

Annals of the Rheumatic Diseases ◽

10.1136/ard.47.6.496 ◽

1988 ◽

Vol 47 (6) ◽

pp. 496-502 ◽

Cited By ~ 25

Author(s):

C G Mackworth-Young ◽

J David ◽

S H Morgan ◽

G R Hughes

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Systemic Lupus ◽

Intravenous Methylprednisolone ◽

Double Blind ◽

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase ib, double-blind, placebo-controlled, dose-escalating trial

Arthritis & Rheumatism ◽

10.1002/art.23047 ◽

2007 ◽

Vol 56 (12) ◽

pp. 4142-4150 ◽

Cited By ~ 219

Author(s):

Maria Dall'Era ◽

Eliza Chakravarty ◽

Daniel Wallace ◽

Mark Genovese ◽

Michael Weisman ◽

...

Keyword(s):

Lupus Erythematosus ◽

B Lymphocyte ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Ib ◽

Multicenter Phase ◽

Immunoglobulin Levels ◽

Dose Escalating

Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus

Rheumatology and Therapy ◽

10.1007/s40744-021-00351-7 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Dale Wright ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

Post Hoc

Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2018-213032 ◽

2018 ◽

Vol 77 (6) ◽

pp. 883-889 ◽

Cited By ~ 33

Author(s):

Joan T Merrill ◽

William R Shanahan ◽

Morton Scheinberg ◽

Kenneth C Kalunian ◽

David Wofsy ◽

...

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Selective Inhibitor ◽

Phase Iii ◽

Systemic Lupus ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

B Cell Activating Factor

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Rheumatology and Therapy ◽

10.1007/s40744-021-00353-5 ◽

2021 ◽

Author(s):

Anca D. Askanase ◽

Enxu Zhao ◽

Julie Zhu ◽

Roman Bilyk ◽

Richard A. Furie

Keyword(s):

Lupus Erythematosus ◽

Controlled Trial ◽

Active Systemic Lupus Erythematosus ◽

Systemic Lupus ◽

Double Blind ◽